Kudos to Pfizer (NYSE: PFE) for its decision to acquire Trillium Therapeutics (NASDAQ: TRIL) . The small biotech's cancer pipeline is a great fit for Pfizer. Trillium's candidates could begin contributing to Pfizer's growth in the second half of the decade, just when the big drugmaker will need a boost due to patent expirations for several of its top drugs.
The price tag of the transaction is close to $2.3 billion . That leaves Pfizer with a huge amount of cash that it could use in making more deals. There's one biotech in particular that I think Pfizer should consider acquiring next.
Image source: Getty Images.
For further details see:
Here's the Biotech Pfizer Should Consider Acquiring Next